Key points are not available for this paper at this time.
This article comprises the consensus reached to update guidance on the use of PET-CT for staging and response assessment for 18Ffluorodeoxyglucose-avid lymphomas in clinical practice and late-phase trials.
Barrington et al. (Tue,) studied this question.